期刊文献+

生脉注射液联合化疗治疗晚期恶性肿瘤的疗效观察 被引量:1

Effect Study on Malignant Tumor Treated with Shengmai Injection Combined with Chemotherapy
原文传递
导出
摘要 目的探讨生脉注射液对晚期恶性肿瘤化疗增效的疗效及作用机制。方法将65例晚期恶性肿瘤辨证属气阴两虚型者,随机分为两组,对照组31例采用常规化疗,治疗组34例在对照组治疗基础上加用生脉注射液。结果治疗组临床获益率为91.2%,对照组为71.0%,两组比较差异有统计学意义(χ^2=4.399,P〈0.05)。结论生脉注射液联合化疗可明显改善晚期恶性肿瘤的症状,减轻化疗的副反应。 Objective To explore the effect of Shengmai injection combined with chemotherapy in treating advanced tumor and its mechanism. Methods 65 patient with malignant tumor, who having the syndrome of yin and qi deficiency, were randomly recruited into a control group and a treatment group. The control group was treated with routine chemotherapy, and the treatment group was treated with routine chemotherapy plus Shengmai injection (60 ml every day). The total effective rate was observed. Results Compared with control group(71.0%), the effective rate of the treatment group (91.2%) showed significant difference (χ^2=4.399, P〈0.05). Conclusion The effect of treating malignant tumor with Shengmai injection combined with chemotherapy is good. The therapy can obviously improve symptoms and reduce side effects of chemotherapy.
作者 李斌 张金路
出处 《国际中医中药杂志》 2009年第6期526-527,共2页 International Journal of Traditional Chinese Medicine
关键词 生脉注射液 晚期恶性肿瘤 Shengmai injection Malignant tumor
  • 相关文献

参考文献5

  • 1中国抗癌协会..新编常见恶性肿瘤诊治规范 头颈部肿瘤分册[M],1999.
  • 2郭勇主编..恶性肿瘤及并发症中西医结合治疗[M].北京:人民军医出版社,2008:178.
  • 3郑筱萸主编..中药新药临床研究指导原则 试行[M].北京:中国医药科技出版社,2002:392.
  • 4孙燕,周际昌.临床肿瘤内科手册.4版.北京:人民卫生出版社,2003:566-569 被引量:6
  • 5王鹏,陈震,黄雯霞,刘鲁明.生脉注射液联合奥沙利铂抗肿瘤实验研究[J].中成药,2006,28(4):533-536. 被引量:9

二级参考文献6

  • 1Kastelan Z,Lukac 3,Derezic D,et al.Lymphocyte subsets,lymphocyte reactivity to mitogens,NK cell activity and neutrophil and monocyte phagocytic functions in patients with bladder carcinoma[J].Anticancer Res,2003,23 (6D):5185-5189. 被引量:1
  • 2Van Sandick J W,Boermeester M A,Gisbertz S S,et al.Lymphocyte subsets and T(h)l/T(h) 2 immune responses in patients with adenocarcinoma of the oesophagusor oespphagogastric junction:relation to pTNM stage and clinical outcome[J].Cancer Immunol Immunother,2003,52(10):617-624. 被引量:1
  • 3Hadden J W.Immunodeficiencyandcancer:prospects for correction[J].Int Immunopharmacol,2003,3(8):1061-1071. 被引量:1
  • 4Diederichsen A C,Hjelmborg J B,Christensen P B,et al.Prognostic value of the CD4 +/CD8 + ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells[J].Cancer Immunol Immunother,2003,52(7):423-428. 被引量:1
  • 5杜丽华,邓学瑞,张才军,谢蒲玲,杨莉.生脉注射液对小鼠免疫功能的影响[J].上海免疫学杂志,2001,21(4):247-248. 被引量:55
  • 6杜卫东,庄舜玖,袁祖荣,程爱群,宋晓华,竺越.腹腔化疗对大肠癌患者细胞免疫功能表达的影响[J].大肠肛门病外科杂志,2003,9(4):246-249. 被引量:8

共引文献13

同被引文献5

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部